CI vs LCTX · P/E 2.4, rev $274.90B vs rev $9.5M
Cigna Corp (CI) versus Lineage Cell Therapeutics Inc (LCTX) — a side-by-side from cached financials, not a winner call.
Cigna Corp (CI) is a healthcare plans company listed on US.
Lineage Cell Therapeutics Inc (LCTX) is a biotechnology company listed on US.
Latest reported CI revenue for 2025-12-31 was $274.90B. Net income was $5.96B. Revenue was up 11.2% from 2024-12-31 to 2025-12-31. CI currently screens at market cap $71.62B and trailing P/E 2.4.
Latest reported LCTX revenue for 2024-12-31 was $9.5M. Net income was -$18.6M. Revenue was up 354.9% from 2023-12-31 to 2024-12-31. LCTX currently screens at market cap $213.6M.
CI currently screens at market cap $71.62B and trailing P/E 2.4. LCTX currently screens at market cap $213.6M.
Not investment advice. Open the CI and LCTX stock pages for the full models.
Not investment advice.